PMID- 37041721
OWN - NLM
STAT- MEDLINE
DCOM- 20230607
LR  - 20240102
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 10
DP  - 2023 May
TI  - CircPTPRA promotes the progression of pancreatic ductal adenocarcinoma via the 
      miR-140-5p/LMNB1 axis.
PG  - 11651-11671
LID - 10.1002/cam4.5869 [doi]
AB  - BACKGROUND: Growing evidences suggest that circular RNAs (circRNAs) are important 
      factors in cancer progression. Nevertheless, the role of circRNAs in the 
      progression of pancreatic ductal adenocarcinoma (PDAC) remains unclear. METHODS: 
      CircPTPRA was identified based on our previous circRNA array data analysis. Wound 
      healing, transwell, and EdU assays were performed to investigate the effect of 
      circPTPRA on the migration, invasion, and proliferation of PDAC cells in vitro. 
      RNA pull-down, fluorescence in situ hybridization (FISH), RNA immunoprecipitation 
      (RIP), and dual-luciferase reporter assays were conducted to verify the binding 
      of circPTPRA with miR-140-5p. Subcutaneous xenograft model was constructed for in 
      vivo experiment. RESULTS: CircPTPRA was significantly upregulated in PDAC tissues 
      and cells compared to normal controls. Moreover, circPTPRA overexpression was 
      positively correlated with lymph node invasion and worse prognosis in PDAC 
      patients. In addition, overexpression of circPTPRA promoted PDAC migration, 
      invasion, proliferation, and epithelial-mesenchymal transition (EMT) in vitro and 
      in vivo. Mechanistically, circPTPRA upregulates LaminB1 (LMNB1) expression by 
      sponging miR-140-5p and ultimately promotes the progression of PDAC. CONCLUSIONS: 
      This study revealed that circPTPRA plays an important role in the progression of 
      PDAC by sponging miR-140-5p. It can be explored as a potential prognostic marker 
      and therapeutic target for PDAC.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Fu, Wen
AU  - Fu W
AUID- ORCID: 0000-0002-9724-2756
AD  - Chongqing Medical University, Chongqing, 400016, China.
AD  - Chongqing Institute of Green and Intelligent Technology, Chinese Academy of 
      Sciences, Chongqing, 400174, China.
AD  - Chongqing School, University of Chinese Academy of Sciences, Chongqing, 400013, 
      China.
AD  - Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, 
      Chongqing, 401147, China.
FAU - Wang, Xianxing
AU  - Wang X
AD  - Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, 
      Chongqing, 401147, China.
FAU - Xiang, Jifeng
AU  - Xiang J
AD  - Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, 
      Chongqing, 401147, China.
FAU - Chen, Shengkai
AU  - Chen S
AD  - Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, 
      Chongqing, 401147, China.
FAU - Xia, Renpei
AU  - Xia R
AD  - Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, 
      Chongqing, 401147, China.
FAU - Xie, Fuming
AU  - Xie F
AD  - Chongqing Medical University, Chongqing, 400016, China.
FAU - Chi, Bojing
AU  - Chi B
AD  - Chinese Academy of Sciences, Beijing, 101400, China.
FAU - Qin, Fanbo
AU  - Qin F
AD  - Chongqing Medical University, Chongqing, 400016, China.
FAU - Li, Zhuo
AU  - Li Z
AD  - Chinese Academy of Sciences, Beijing, 101400, China.
FAU - Mou, Li
AU  - Mou L
AD  - NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population 
      and Family Planning Science and Technology Research Institute, Chongqing, 400020, 
      China.
FAU - Xie, Chuanming
AU  - Xie C
AD  - Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of 
      Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University 
      (Army Medical University), Chongqing, 400038, China.
FAU - Wang, Huaizhi
AU  - Wang H
AD  - Chongqing Medical University, Chongqing, 400016, China.
AD  - Department of Hepatopancreatobiliary Surgery, Chongqing General Hospital, 
      Chongqing, 401147, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230411
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - 0 (Mirn140 microRNA, human)
SB  - IM
MH  - Humans
MH  - *MicroRNAs/genetics/metabolism
MH  - RNA, Circular/genetics/metabolism
MH  - In Situ Hybridization, Fluorescence
MH  - *Pancreatic Neoplasms/pathology
MH  - *Carcinoma, Pancreatic Ductal/metabolism
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Gene Expression Regulation, Neoplastic
MH  - Cell Movement/genetics
PMC - PMC10242365
OTO - NOTNLM
OT  - CircPTPRA
OT  - LMNB1
OT  - MiR-140-5p
OT  - epithelial-mesenchymal transition
OT  - pancreatic ductal adenocarcinoma
EDAT- 2023/04/13 06:00
MHDA- 2023/06/07 06:42
PMCR- 2023/04/11
CRDT- 2023/04/12 01:13
PHST- 2023/03/01 00:00 [revised]
PHST- 2022/11/16 00:00 [received]
PHST- 2023/03/16 00:00 [accepted]
PHST- 2023/06/07 06:42 [medline]
PHST- 2023/04/13 06:00 [pubmed]
PHST- 2023/04/12 01:13 [entrez]
PHST- 2023/04/11 00:00 [pmc-release]
AID - CAM45869 [pii]
AID - 10.1002/cam4.5869 [doi]
PST - ppublish
SO  - Cancer Med. 2023 May;12(10):11651-11671. doi: 10.1002/cam4.5869. Epub 2023 Apr 
      11.